GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relay Therapeutics Inc (NAS:RLAY) » Definitions » Beneish M-Score

Relay Therapeutics (Relay Therapeutics) Beneish M-Score : 22.23 (As of May. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relay Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 22.23 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Relay Therapeutics's Beneish M-Score or its related term are showing as below:

RLAY' s Beneish M-Score Range Over the Past 10 Years
Min: -8.95   Med: 8.09   Max: 32.39
Current: 22.23

During the past 6 years, the highest Beneish M-Score of Relay Therapeutics was 32.39. The lowest was -8.95. And the median was 8.09.


Relay Therapeutics Beneish M-Score Historical Data

The historical data trend for Relay Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relay Therapeutics Beneish M-Score Chart

Relay Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -8.95 -2.64 12.25

Relay Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.60 -4.72 9.16 12.25 22.23

Competitive Comparison of Relay Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Relay Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relay Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Relay Therapeutics's Beneish M-Score falls into.



Relay Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Relay Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0+0.528 * 1+0.404 * 1.2659+0.892 * 29.7365+0.115 * 0.7268
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.0364+4.679 * -0.062836-0.327 * 0.8467
=22.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.00 Mil.
Revenue was 10.007 + -0.001 + 25.202 + 0.119 = $35.33 Mil.
Gross Profit was 10.007 + -0.001 + 25.202 + 0.119 = $35.33 Mil.
Total Current Assets was $770.10 Mil.
Total Assets was $841.44 Mil.
Property, Plant and Equipment(Net PPE) was $66.33 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.47 Mil.
Selling, General, & Admin. Expense(SGA) was $75.17 Mil.
Total Current Liabilities was $37.14 Mil.
Long-Term Debt & Capital Lease Obligation was $47.16 Mil.
Net Income was -81.387 + -83.495 + -65.734 + -98.505 = $-329.12 Mil.
Non Operating Income was 1.857 + 2.068 + 1.198 + 2.138 = $7.26 Mil.
Cash Flow from Operations was -50.323 + -89.188 + -75.397 + -68.601 = $-283.51 Mil.
Total Receivables was $5.23 Mil.
Revenue was 0.226 + 0.253 + 0.344 + 0.365 = $1.19 Mil.
Gross Profit was 0.226 + 0.253 + 0.344 + 0.365 = $1.19 Mil.
Total Current Assets was $958.39 Mil.
Total Assets was $1,037.56 Mil.
Property, Plant and Equipment(Net PPE) was $74.29 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.35 Mil.
Selling, General, & Admin. Expense(SGA) was $69.49 Mil.
Total Current Liabilities was $70.47 Mil.
Long-Term Debt & Capital Lease Obligation was $52.31 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 35.327) / (5.231 / 1.188)
=0 / 4.403199
=0

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.188 / 1.188) / (35.327 / 35.327)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (770.1 + 66.334) / 841.441) / (1 - (958.388 + 74.294) / 1037.56)
=0.005951 / 0.004701
=1.2659

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=35.327 / 1.188
=29.7365

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.352 / (4.352 + 74.294)) / (5.467 / (5.467 + 66.334))
=0.055337 / 0.076141
=0.7268

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(75.17 / 35.327) / (69.489 / 1.188)
=2.127834 / 58.492424
=0.0364

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((47.159 + 37.144) / 841.441) / ((52.306 + 70.467) / 1037.56)
=0.100189 / 0.118329
=0.8467

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-329.121 - 7.261 - -283.509) / 841.441
=-0.062836

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Relay Therapeutics has a M-score of 22.23 signals that the company is likely to be a manipulator.


Relay Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Relay Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Relay Therapeutics (Relay Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
399 Binney Street, 2nd Floor, Cambridge, MA, USA, 02139
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Executives
Peter Rahmer officer: See remarks C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Thomas Catinazzo officer: Vice President, Finance C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Donald A Bergstrom officer: See Remarks 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Adams officer: General Counsel 750 LEXINGTON AVENUE, NEW YORK NY 10022
Sanjiv Patel director, officer: President and CEO C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Andy Porter officer: See Remarks C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Mark Murcko director C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Sekar Kathiresan director 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jami Rubin director C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Douglas S Ingram director 2525 DUPONT DR, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Svf Pauling (cayman) Ltd 10 percent owner 27 HOSPITAL ROAD, GEORGE TOWN, GEORGE TOWN E9 KY1-9008
Picularium, Llc 10 percent owner 1166 AVENUE OF THE AMERICAS, NINTH FLOOR, NEW YORK NY 10036
Laura Shawver director 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518

Relay Therapeutics (Relay Therapeutics) Headlines